These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 22413955

  • 1. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
    Van Welzen B, Mudrikova T, Arends J, Hoepelman A.
    HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
    [Abstract] [Full Text] [Related]

  • 2. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S.
    Clin Infect Dis; 2005 Feb 15; 40(4):588-93. PubMed ID: 15712082
    [Abstract] [Full Text] [Related]

  • 3. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY, Cheng CY, Liu CE, Lee YC, Yang CJ, Tsai MS, Cheng SH, Lin SP, Lin DY, Wang NC, Lee YC, Sun HY, Tang HJ, Hung CC.
    PLoS One; 2017 Feb 15; 12(2):e0171596. PubMed ID: 28222098
    [Abstract] [Full Text] [Related]

  • 4. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, Petzold D, Hartmann M.
    Eur J Med Res; 2008 Jul 28; 13(7):343-8. PubMed ID: 18700192
    [Abstract] [Full Text] [Related]

  • 5. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD.
    Hepatology; 2002 Jan 28; 35(1):182-9. PubMed ID: 11786975
    [Abstract] [Full Text] [Related]

  • 6. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W, Lueangniyomkul A, Manosuthi W.
    Southeast Asian J Trop Med Public Health; 2011 May 28; 42(3):651-8. PubMed ID: 21706943
    [Abstract] [Full Text] [Related]

  • 7. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, Merino D, de Los Santos-Gil I, Macías J, González-Serrano M, Camacho A, Parra-García G, Pineda JA, SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    J Antimicrob Chemother; 2011 Nov 28; 66(11):2605-14. PubMed ID: 21903660
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
    Li ZC, Li HJ, Dai LL, Gao YQ, Cai WP, Li HY, Huang XJ, Zhang T, Wu H.
    Chin Med J (Engl); 2010 Dec 28; 123(24):3587-90. PubMed ID: 22166636
    [Abstract] [Full Text] [Related]

  • 12. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
    Rivero A, Mira JA, Pineda JA.
    J Antimicrob Chemother; 2007 Mar 28; 59(3):342-6. PubMed ID: 17255142
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C, Costarelli S, De Silvestri A, Quiros-Roldan E, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G, BHCC Study Group.
    Drug Saf; 2007 Mar 28; 30(12):1161-9. PubMed ID: 18035868
    [Abstract] [Full Text] [Related]

  • 15. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F, Torralba M.
    J HIV Ther; 2002 Nov 28; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J, Amador C, Benito C, Fenoll V, Pasquau F.
    Int J STD AIDS; 2003 Nov 28; 14(11):776-81. PubMed ID: 14624743
    [Abstract] [Full Text] [Related]

  • 18. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.
    AIDS; 2001 Jul 06; 15(10):1261-8. PubMed ID: 11426070
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
    Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo Caputo S, Di Perri G, Filice G, Tinelli C, Carosi G, EPOKA-MASTER Study Group.
    BMC Infect Dis; 2005 Jul 14; 5():58. PubMed ID: 16018804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.